Últimas noticias sobre MoonLake (NASDAQ:MLTX) Bolsa

MoonLake

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Dollar General

Markets

CRDO

FERG

MLTX

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: DG, CRDO, SIG, MLTX y FERG.

5 acciones en el foco este martes: DG, CRDO, SIG, MLTX y FERG

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics

<h3 class="wp-block-heading">New On The Block</h3>
Byron Allen's Allen Media Group has hired Moelis &amp; Company to explore a sale of its TV stations across 21 markets. The company spent over $1 billion acquiring Big Four network affiliates (ABC, NBC, CBS, FOX) over the past six years. 
It is now looking to cash out and reduce debt. Deadline <a href="https://deadline.com/2025/06/allen-media-group-hires-investment-bank-to-sell-tv-stations-1236420381/">reported</a> that the TV stations have received multiple offers. 
Also for sale: 
<ul class="wp-block-list">
<li>Jefferies is shopping around PatientPoint, a health marketing and ad agency, according <a href="https://www.axios.com/pro/health-tech-deals/2025/06/04/patientpoint-jefferies-sale">to</a> Axios. L Catterton, Littlejohn &amp; Co. and Transformation Capital are on the sell side. </li>
<li>Just three years ago, private equity firm One Equity Partners <a href="https://www.oneequity.com/news/one-equity-partners-completes-investment-in-infucare-rx-a-leading-home-infusion-therapy-provider/">completed</a> a strategic investment in infusion provider InfuCare. Today? It&#8217;s looking to get rid of it. According to Axios, JPMorgan is <a href="https://www.axios.com/pro/health-tech-deals/2025/06/03/infucare-one-equity-jpmorgan-sale">looking</a> for a buyer. </li>
<li>Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) received a <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report">bid exceeding $3 billion</a> from Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>). MoonLake turned down the initial offer, but talks are reportedly revived. The potential purchase signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.</li>
</ul>
<h3 class="wp-block-heading">Updates From The Block</h3>
<ul class="wp-block-list">
<li>Post Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POST#NYSE">POST</a>) is forking over $880 million—including assumed debt—to buy 8th Avenue Food &amp; Provisions. That means brands like Ronzoni pasta will go back into Post&#8217;s pantry. <a href="https://www.wsj.com/articles/post-holdings-to-buy-ronzoni-pasta-owner-8th-avenue-food-cf8f454c?mod=deals_news_article_pos2">Per</a> The Wall Street Journal, the private-label brands originally got spun off into 8th Avenue in 2018 with help from private equity firm THL. Post plans to wipe out 8th Avenue's net debt and pick up the tab for all equity interests, including $111 million in finance leases. All in, the transaction is expected to cook up $15 million in annual synergies by the end of fiscal 2026. If Post closes by July 1, it expects 2026 to be more profitable (on an adjusted basis) than initially expected.</li>
</ul>
<ul class="wp-block-list">
<li>Rosebank Industries (LON: ROSE) is once again in talks to buy Electrical Components International (ECI), a wire harnesses manufacturer, for about $1.9 billion, Reuters reported. Rosebank was in talks to buy ECI in February but dropped the plans in March.</li>
</ul>
<ul class="wp-block-list">
<li>Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU. The acquisition will also include elenestinib, a next-generation medicine for SM, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential for immunology diseases. Sanofi will pay&nbsp;$129&nbsp;per share in cash, representing an equity value <a href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout">of roughly&nbsp;$9.1 billion</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Suzano S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUZ#NYSE">SUZ</a>) is acquiring a 51% stake in a new $3.4 billion tissue products joint venture with Kimberly-Clark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NASDAQ">KMB</a>), <a href="https://www.benzinga.com/m-a/25/06/45797473/tissue-titans-unite-suzano-kimberly-clark-form-3-4-billion-global-jv">paying $1.734 billion in cash</a>. Kimberly-Clark will retain a 49% stake. The Netherlands-based venture will produce and distribute toilet paper and facial tissues in 70 countries, with 22 factories across 14 countries, employing about 9,000 people. The facilities have an annual capacity of 1 million tonnes and generated $3.3 billion in net sales in 2024.</li>
</ul>
<h3 class="wp-block-heading">Off The Block</h3>
<ul class="wp-block-list">
<li>Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45740112/robinhood-completes-200-million-bitstamp-deal-gains-access-to-500k-crypto-users-and-95-million-revenue-stream">completed its $200 million acquisition</a> of Bitstamp, a crypto exchange that had raised around $40 million from firms like Pantera Capital and Ripple.</li>
</ul>
<ul class="wp-block-list">
<li>Cactus Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) <a href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach">formed a joint venture</a> with Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), taking a 65% stake and operational control of Baker Hughes&#8217; Surface Pressure Control (SPC) business. Baker Hughes will retain a 35% stake. The new venture, separate from Cactus' current pressure control unit, will focus on international wellhead and production tree systems.</li>
</ul>
<ul class="wp-block-list">
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) is <a href="https://www.benzinga.com/pressreleases/25/06/b45719054/guardian-pharmacy-services-expands-pacific-northwest-footprint-with-acquisition-of-washington-base" target="_blank" rel="noreferrer noopener">entering the Pacific Northwest market</a> via acquisition. Mercury Pharmacy Services, a provider of long-term care pharmacy solutions, agreed to a price, but <a href="https://www.benzinga.com/m-a/25/06/45723960/guardian-pharmacy-strengthens-us-footprint-with-new-seattle-area-acquisition">the amount remains undisclosed</a>.</li>
</ul>
<h3 class="wp-block-heading">Bankruptcy Block</h3>
<ul class="wp-block-list">
<li>AI startup Builder.ai has filed for Chapter 7 bankruptcy in Delaware after creditors seized most of its cash, citing overstated 2024 sales projections—by a staggering 300%. Once valued at $1.5 billion, Builder.ai is now the biggest AI collapse since the ChatGPT-driven investment boom began. According <a href="https://www.bloomberg.com/news/articles/2025-06-05/builder-ai-files-for-bankruptcy-after-creditors-seize-accounts?sref=TBDibEcD">to</a> Bloomberg, the fallout was fueled by revelations that Builder.ai allegedly faked business with Indian social media firm VerSe Innovation to inflate revenues. VerSe co-founder Umang Bedi denies any wrongdoing, calling the claims "baseless and false."</li>
</ul>
<ul class="wp-block-list">
<li>Hooters closed some 30 corporate-owned restaurants and explained that it has <a href="https://www.businesswire.com/news/home/20250331979797/en/Hooters-of-America-Takes-Strategic-Action-to-Continue-its-Iconic-Legacy-Under-Pure-Franchise-Business-Model" target="_blank" rel="noreferrer noopener">no plans </a>to shut down any other locations. The Atlanta, Georgia-based restaurant chain went <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">bankrupt earlier this year</a>.</li>
</ul>
<ul class="wp-block-list">
<li>Alex Jones may see his personal assets — including guns, cars, and homes — sold by the end of the year, according to the Houston Chronicle, <a href="https://www.houstonchronicle.com/news/houston-texas/texas/article/alex-jones-personal-assets-sales-bankruptcy-20361565.php">citing</a> a bankruptcy trustee. The potential sale would mark the nearing end of his two-and-a-half-year bankruptcy process. Jones, who created the far-right conspiracy theory website Infowars, filed for bankruptcy in 2022 after being ordered to pay nearly $1.5 billion to families of Sandy Hook shooting victims for defamation.</li>
</ul>
<h3 class="wp-block-heading">Notes From The Block</h3>
A studio's IP portfolio and game development pipeline are critical for video game investors. A major acquirer in the sector is GDEV Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>). The Cyprus-based company has made three M&amp;A deals and spent $100 million on studio acquisitions since 2022. 
This week, Andrey Fadeev drafted <a href="https://www.benzinga.com/m-a/25/06/45722621/gdevs-founder-ceo-evaluates-m-a-deals-using-these-5-metrics">a listicle of key metrics</a> GDEV uses for M&amp;A evaluation.
<ol class="wp-block-list">
<li>LTV/CAC Ratio – Measures how efficiently a studio converts user acquisition spend into revenue. A ratio above 1.0 indicates profitable user growth.</li>
<li>Retention Rates (D1, D7, D30) – Track user engagement over time. High retention signals strong gameplay and monetization potential. Benchmarks vary by genre.</li>
<li>ARPU/ARPPU – Indicate monetization efficiency. ARPU includes all users; ARPPU focuses on paying users. Higher ARPU justifies higher CAC.</li>
<li>DAU/MAU Ratio – Shows user engagement depth. A ratio above 20% is considered strong.</li>
<li>EBITDA – Reflects core operational profitability and financial health. High EBITDA margins show sustainable growth and efficiency.</li>
</ol>
In 2024, video game M&amp;A activity reached $27.3 billion, underscoring the sector's immense growth and investment appeal. C-suite executives would be wise to consider these metrics when searching for their next target. 
<a href="https://www.benzinga.com/markets/asset-sales/25/05/45702349/deal-dispatch-beauty-brand-behavioral-health-firms-hit-auction-block">For last week&#8217;s edition of Deal Dispatch, click here</a>.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45816311/conagra-sells-seafood-brands-for-55m-as-it-sharpens-focus-on-core-business">Conagra Sells Seafood Brands For $55M As It Sharpens Focus On Core Business</a></li>
</ul>
Image created using a photo from Shutterstock.

Asset Sales

BPMC

GDEV

GRDN

HOOD

KEYS

POST

ROSE

SNOW

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

RBC Capital analyst Brian Abrahams reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform and maintains $67 price target.

News

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on MoonLake, Maintains $67 Price Target

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Tuesday.
Shares of Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) rose sharply during Tuesday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/markets/earnings/25/06/45746739/signet-cfo-says-current-tariffs-factored-into-raised-fy26-guidance-stock-soars">raised its FY26 guidance</a>.
The company posted revenue of $1.54 billion, a 2% increase from the prior year, surpassing analysts' consensus estimate of $1.49 billion. Adjusted EPS of $1.18 beat the consensus estimate of $1.07.
Signet Jewelers shares jumped 12.1% to $74.89 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares jumped 23.1% to $77.29 following upbeat quarterly results.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 19.3% to $14.08.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) gained 18.5% to $4.15 after the company announced a $50 million stock repurchase program.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) gained 18.4% to $142.37 on possible continued strength following its data center deal announced yesterday with Applied Digital.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 16.7% to $13.77.</li>
<li>LiveWire Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) rose 15.3% to $4.3801.</li>
<li>Energy Fuels Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#NYSE">UUUU</a>) surged 15% to $5.61 after the company reported record Uranium production, announced it expanded its resource base based on a technical report of its Bullfrog project in Utah, and is engaging with consultants for an accelerated permitting process with regulators in New Mexico.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) gained 14.8% to $47.27 following reports that Merck is looking to acquire the company in a deal valued at over $3 billion.</li>
<li>Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) rose 13.6% to $204.82 following better-than-expected quarterly results.</li>
<li>Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) jumped 13.5% to $110.24 after the company reported first-quarter 2025 earnings on Tuesday.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) rose 13.2% to $8.08.</li>
<li>Sitio Royalties Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STR#NYSE">STR</a>) surged 13.2% to $19.61 after an announcement that Viper Energy will acquire the company through a $4.1 billion all-equity deal.</li>
<li>enCore Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EU#NASDAQ">EU</a>) gained 12.5% to $2.1601.</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) rose 11.4% to $48.06 after Morgan Stanley and B. Riley Securities upgraded the stock to Overweight and Buy, respectively. Additionally, the company received several price target increases.</li>
<li>Algonquin Power &amp; Utilities Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) gained 11.1% to $5.96 after the company provided adjusted EPS guidance from 2025 through 2027.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) rose 9.4% to $8.20 after the company signed an MOU with Abdul Latif Jameel of Saudi Arabia to explore opportunities in establishing a distribution agreement.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) jumped 9% to $45.89. The FDA granted Guardant Health&#8217;s Shield Multi-Cancer Detection Test Breakthrough Device Designation.</li>
<li>TTM Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) gained 7.1% to $31.94.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

Trading Ideas

CRWV

JOBY

KYMR

LVWR

RBBN

TTMI

UUUU

Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday

WIIM

MoonLake Immunotherapeutics shares are trading higher following reports that Merck is looking to acquire the company in a deal valued at over $3 billion.

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock increased by 159.9% to $4.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.3 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock moved upwards by 128.88% to $3.25. The market value of their outstanding shares is at $18.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock rose 60.82% to $1.56. The market value of their outstanding shares is at $56.4 million. </li>
<li>Kiora Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPRX#NASDAQ">KPRX</a>) stock moved upwards by 59.29% to $4.54. The market value of their outstanding shares is at $13.8 million. </li>
<li>Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) stock rose 28.75% to $5.32. The market value of their outstanding shares is at $145.7 million. </li>
<li>MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) stock increased by 21.59% to $50.05. The company's market cap stands at $3.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares fell 20.0% to $1.76 during Tuesday's pre-market session. The company's market cap stands at $25.2 million. </li>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares decreased by 12.14% to $4.31. The market value of their outstanding shares is at $38.6 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 11.28% to $2.14. The company's market cap stands at $3.0 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 10.26% to $0.33. The market value of their outstanding shares is at $1.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) shares decreased by 8.73% to $9.95. The company's market cap stands at $15.0 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares declined by 7.51% to $0.07. The market value of their outstanding shares is at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGEN

CLNN

ESLA

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

MODV

NIVF

ONCO

PRPO

PSTV

TRAW

VERO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

US drug giant Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a bid exceeding $3 billion.
While MoonLake turned down the initial offer, talks may be revived.
The potential deal signals renewed dealmaking activity as investor pressure has mounted on Merck to secure new assets, especially as its blockbuster <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cancer drug Keytruda</a> faces patent expiration as early as 2028.
MoonLake Immunotherapeutics&#8217; lead development asset sonelokimab is a novel investigational Nanobody&nbsp;for inflammatory diseases.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/05/45701905/merck-kandlelit-trials-spark-hope-lung-cancer-trials" target="_blank" rel="noreferrer noopener">Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers</a>
Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
Merck is also grappling with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million" rel="noreferrer noopener">falling sales of its Gardasil</a> vaccine in China and underwhelming uptake of its new hypertension drug, Winrevair.
Per a Financial Times <a target="_blank" href="https://www.ft.com/content/5899ea69-e5fe-49f1-8ada-79f26c9254d8" rel="noreferrer noopener">report</a> on Monday, Merck made a nonbinding offer earlier this year, valuing MoonLake above its $2.6 billion market capitalization.
Founded in 2021 by former McKinsey partner Jorge Santos da Silva, MoonLake has garnered investor interest, with its stock price climbing nearly 50% over the past two years.
The FT report added that the company hired Goldman Sachs and Morgan Stanley to advise on the sale process.
Over the past year, Merck shares have dropped 39%, significantly underperforming the broader S&amp;P 500 pharmaceutical index, which declined by 11%.
In April, MoonLake Immunotherapeutics entered into an agreement with Hercules Capital, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTGC#NASDAQ">HTGC</a>) for up to $500 million in non-dilutive capital, of which $75 million will be drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44624282/moonlake-secures-up-to-500-million-in-non-dilutive-financing-from-hercules-capital-and-announces-a" rel="noreferrer noopener">strategy and funding needs</a>.
In January, MoonLake announced that patients have been screened in three new trials across three new indications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42869804/moonlake-initiates-three-new-clinical-trials-and-further-expands-the-portfolio-of-indications-for-" rel="noreferrer noopener">to evaluate sonelokimab</a>.
The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), and axial spondyloarthritis (axSpA), as well as adult patients with HS and active psoriatic arthritis (PsA).
This increases the number of clinical trials led by MoonLake to ten and aligns with the company&#8217;s plan to enroll over 3,000 patients in clinical trials with sonelokimab since its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45358838/moonlake-immunotherapeutics-reports-first-quarter-2025-financial-results-and-provides-a-business-u" rel="noreferrer noopener">founding in 2021</a>.
Price Action: MLTX stock is trading higher by 21.1% to $49.84 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45731052/warner-bros-debt-downgrade-is-an-ironically-positive-event-analyst" target="_blank" rel="noreferrer noopener">Warner Bros&#8217; Debt Downgrade Is An &#8216;Ironically Positive&#8217; Event: Analyst</a></li>
</ul>
Photo by tada images via Shutterstock

Biotech

Health Care

Rumors

General

HTGC

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

MLTX: 30% &#x7C; <a href="https://www.benzinga.com//node/45735279">MoonLake Immunotherapeutics shares are trading higher following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.</a>
&nbsp;
CRDO: 17% &#x7C; <a href="https://www.benzinga.com//node/45734618">Credo Technology Group Holding shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 sales guidance above estimates.</a>
&nbsp;
HIMS: 4% &#x7C; <a href="https://www.benzinga.com//node/45742535">Hims &amp; Hers Announces Strategic Acquisition Of European Digital Health Leader ZAVA To Drive Major Growth In Key Markets</a>

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Market-Moving News for June 3rd

Shares of Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) rose sharply in today's pre-market trading following upbeat <a href="https://www.benzinga.com/quote/CRDO/news">quarterly results</a>.
The company reported fourth-quarter revenue of $170.03 million, beating analyst estimates of $162.96 million. The connectivity solutions company reported fourth-quarter adjusted earnings of 35 cents per share, beating analyst estimates of 28 cents per share, according to Benzinga Pro.
Credo Technology Group shares jumped 14.3% to $71.60 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares jumped 192.4% to $5.03 in pre-market trading. NewGenIvf Group recently announced a $30 million investment in Solana Digital Asset staking.</li>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) surged 36.4% to $0.5878 in pre-market trading after the company announced that it will raised $13.5 million through the sale of 18 million common shares at $0.75 each to non-US investors.</li>
<li>Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) rose 36.2% to $1.12 in pre-market trading. Revelation Biosciences recently announced a $4 million public offering.</li>
<li>Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) jumped 31.4% to $2.19 in pre-market trading. Eyenovia recently provided an update on its merger with Betaliq and reported better-than-expected first-quarter EPS results.</li>
<li>Northern Dynasty Minerals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) surged 25.2% to $1.44 in pre-market trading. Northern Dynasty Minerals received payment of $12 million representing the third tranche investment under the company's royalty agreement dated July 26, 2022.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) gained 24% to $4.86 in pre-market trading after falling 35% on Monday.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) climbed 21.1% to $49.84 in pre-market trading following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.</li>
<li>Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) rose 18.4% to $4.89 in pre-market trading after jumping 20% on Monday.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) gained 8.4% to $122.62 in pre-market trading. BioNTech shares jumped 18% on Monday after the company entered into an agreement with Bristol Myers Squibb to advance bispecific antibody BNT327 for solid tumors.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares dipped 16% to $0.4119 in pre-market trading after jumping over 75% on Monday.</li>
<li>CleanCore Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#NYSE">ZONE</a>) shares fell 17.6% to $2.39 in pre-market trading after gaining around 32% on Monday.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) fell 16.7% to $0.30 in pre-market trading.</li>
<li>ModivCare Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) fell 15% to $1.87 in pre-market trading after jumping 96% on Monday.</li>
<li>AgEagle Aerial Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#NYSE">UAVS</a>) shares tumbled 14.3% to $1.08 in pre-market trading after jumping 63% on Monday.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) declined 14.2% to $2.25 in pre-market trading after gaining 27% on Monday.</li>
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) fell 5.9% to $2.40 in pre-market trading after jumping over 18% on Monday.</li>
<li>Bumble Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NYSE">BMBL</a>) fell 5.8% to $5.41 in today's pre-market trading.</li>
<li>Pearson plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSO#NYSE">PSO</a>) dipped 5% to $15.24 in pre-market trading.</li>
<li>GCL Global Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCL#NASDAQ">GCL</a>) shares fell 4.8% to $2.40 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li>W<a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">all Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

BMBL

BMGL

BNAI

BNTX

EYEN

MREO

PSIG

REVB

SISI

SOAR

UAVS

ZONE

Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket

U.S. stock futures fell on Tuesday, pulling back after a higher close on Monday. Futures of major benchmark indices declined in premarket.
Trade tensions escalated as <a href="https://www.benzinga.com/news/politics/25/06/45715447/xi-jinpings-china-dismisses-trumps-groundless-accusations-on-geneva-trade-deal-breach-vows-strong-retaliation">China&#8217;s Commerce Ministry dismissed</a> President Donald Trump&#8216;s allegations that Beijing had violated the Geneva trade agreement. The ministry asserted that China had fully implemented and consistently honored the deal struck last month in Geneva.
The Chinese government declared that the U.S. had &#8220;groundlessly&#8221; accused China of breaching the trade agreement. It pledged to take strong action to protect its interests.
Meanwhile, the 10-year Treasury bond yielded 4.41% and the two-year bond was at 3.92%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 95.3% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.43%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.42%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.49%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.45% at $590.04, while the QQQ declined 0.36% to $521.35, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
U.S. stocks wrapped up Monday higher. Most sectors within the S&amp;P 500 ended positively, spearheaded by strong performances in energy, communication services, and information technology stocks. However, industrial stocks went against the grain, finishing the session lower.
Wall Street closed out last month strong, with the S&amp;P 500 up more than 6.2% in May and the Nasdaq surging 9.6%. Both indices had their best months since November 2023, while the Dow gained 3.9% for the month.
Trade tensions flared as President Trump announced weekend plans to <a href="https://www.benzinga.com/news/topics/25/05/45708977/trump-doubles-steel-tariffs-to-50-saying-it-will-secure-american-jobs-backs-us-steels-takeover-by-japans-nippon">double tariffs on steel and aluminum</a> imports to 50% starting June 4. 
In corporate news, Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) reported better-than-expected third-quarter results. Meanwhile, Lyra Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares skyrocketed over 310% on Monday after its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.
On the economic front, the ISM manufacturing PMI dropped to 48.5 in May from April&#8217;s 48.7, missing market estimates of 49.5. U.S. construction spending also fell, declining 0.4% month-over-month in April to an annual rate of $2,152.4 billion, following a revised 0.8% drop in March.
The Dow Jones index ended 35 points or 0.084% higher at 42,305.48, whereas the S&amp;P 500 index rose 0.41% to 5,935.94. Nasdaq Composite advanced 0.67% to 19,242.61, and the small-cap gauge, Russell 2000, gained 0.19% to end at 2,070.16.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.67%</td>
<td>19,242.61</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.041%</td>
<td>5,935.94</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.084%</td>
<td>42,305.48</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.19%</td>
<td>2,070.16</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
As the S&amp;P 500 index rebounded from its April slump, Adam Turnquist, LPL Financial's chief technical strategist, pointed to strong indicators of a genuine recovery, noting the index&#8217;s reversal of its short-term downtrend and a doubling of its uptrend during this period.
A chart from LPL Financial illustrates this shift: on April 8, the S&amp;P 500&#8217;s uptrend accounted for just 29.4%, with downtrends at 70.2%. By May 29, however, the index had swiftly recovered, with uptrends doubling to 60% and downtrends decreasing to 39%.
LPL Financial attributed this change to <a href="https://www.benzinga.com/markets/equities/25/06/45739065/sp-500-reverses-short-term-downtrend-after-april-lows-technical-evidence-shows-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally">significant technical progress</a> throughout May. He explained, "The index has reversed a short-term downtrend and continues to hold above its recent price gap above the 200-day moving average (dma)."
Turnquist suggests that a close above the May high of 5,969 points could pave the way for the index to retest its previous high of 6,144 points.
He emphasized, "There is a growing list of technical evidence that suggests this recovery is real, and not a ‘bull trap' or ‘bear market rally.' For investors, this means dips above support should be used as buying opportunities."
This positive outlook follows a strong May for the broader market, which saw a 6.2% gain—its best month since November 2023 and its strongest May since 1990. Turnquist also noted that historically, when the index rallies 3% or more in May, a month often associated with the &#8220;Sell in May and Go Away&#8221; adage, year-end returns average 8.9%, with positive returns in 73% of such periods.
Meanwhile, the Senior Economist at WisdomTree and former professor at the University of Pennsylvania, Jeremy Siegel, said, &#8220;I remain bullish on equities presuming tariffs remain in the 10% for all, 30% for China, range.&#8221;
Highlighting that Trump has doubled the tariffs on steel and aluminum, Seigel added, &#8220;If he goes no further, the current upward trend can continue. The market's resilience, despite noise on tariffs, inflation, and politics, tells me that investors see the same economy I do: strong productivity, solid consumer spending, and stabilizing inflation.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>April&#8217;s factory orders and job openings data will be out by 10:00 a.m. ET.</li>
<li>Chicago Fed President Austan Goolsbee will speak at 12:45 p.m., Federal Reserve Governor Lisa Cook will speak at 1:00 p.m., and Dallas Fed President Lorie Logan will speak at 3:30 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) rose 1.37% in premarket on Tuesday as analysts expect it to report quarterly earnings of $1.48 per share on revenue of $10.31 billion, before the opening bell.</li>
<li>Signet Jewelers Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) was up 1.80% ahead of its earnings, which are supposed to be released before the opening bell. Analysts expect earnings of $1.03 per share on revenue of $1.52 billion.</li>
<li>Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) declined 0.99% as analysts expect it to report quarterly earnings of $2.02 per share on revenue of $7.42 billion, before the opening bell.</li>
<li>Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) jumped 12.8% after reporting fourth-quarter revenue of $170.03 million, beating analyst estimates of $162.96 million.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) surged 19.05% following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.</li>
<li>Donaldson Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) fell 0.39% ahead of its earnings, which are supposed to be released before the opening bell. Analysts expect earnings of 95 cents per share on revenue of $933.45 million.</li>
<li>Ollie&#8217;s Bargain Outlet Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) edged 0.45% higher as analysts expect it to report quarterly earnings of 71 cents per share on revenue of $565.75 million, before the opening bell.</li>
<li>Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) was trading 0.90% higher after the successful launch of the 10th Electron mission for multi-launch customer BlackSky.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.34% to hover around $62.73 per barrel.
Gold Spot US Dollar fell 0.58% to hover around $3,361.51 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.21% at the 98.9110 level.
Asian markets closed mixed on Tuesday as India's S&amp;P BSE Sensex, Japan's Nikkei 225 indices declined. While South Korea's Kospi, Australia's ASX 200, China&#8217;s CSI 300, and Hong Kong's Hang Seng indices rose. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45740592/trump-sets-july-8-deadline-for-trade-deals-demands-best-offers-from-global-partners-by-wednesday-report">Trump Sets July 8 Deadline For Trade Deals, Demands Best Offers From Global Partners By Wednesday: Report</a></li>
</ul>
Photo courtesy: Shutterstock

LYRA

OLLI

RKLB

US Stocks Likely To Open Lower: Expert Highlights Technical Analysis Showing S&P 500's 'Recovery Is Real' And Not A 'Bull Trap' Or 'Bear Market Rally'

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) to report quarterly earnings at $1.48 per share on revenue of $10.31 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Dollar General shares gained 0.6% to $97.70 in after-hours trading.</li>
<li>Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) reported fourth-quarter revenue of $170.03 million, beating analyst estimates of $162.96 million. The connectivity solutions company reported fourth-quarter adjusted earnings of 35 cents per share, beating analyst estimates of 28 cents per share, according to Benzinga Pro. Credo Technology shares jumped 12.2% to $70.30 in the after-hours trading session.</li>
<li>Analysts are expecting Signet Jewelers Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) to post quarterly earnings at $1.03 per share on revenue of $1.52 billion. The company will release earnings before the markets open. Signet shares rose 1% to $67.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) shares rose sharply in after-hours trading on Monday following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion. MoonLake Immunotherapeutics shares jumped 19% to $48.99 in the after-hours trading session.</li>
<li>Analysts expect Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) to post quarterly earnings at $2.02 per share on revenue of $7.42 billion before the opening bell. Ferguson shares fell 0.2% to $179.95 in after-hours trading.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: Pamela Brick / Shutterstock.com

Dollar General, Signet Jewelers And 3 Stocks To Watch Heading Into Tuesday

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock moved upwards by 47.4% to $0.72 during Monday's after-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) shares moved upwards by 15.95% to $47.75. The company's market cap stands at $3.0 billion. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares rose 8.91% to $0.32. The company's market cap stands at $32.3 million. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) stock rose 8.19% to $6.6. The company's market cap stands at $109.0 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares moved upwards by 7.92% to $32.0. The market value of their outstanding shares is at $209.9 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares rose 7.27% to $0.51. The company's market cap stands at $10.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock fell 22.7% to $1.7 during Monday's after-market session. The market value of their outstanding shares is at $24.4 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) shares fell 17.82% to $1.43. The company's market cap stands at $52.7 million. </li>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) stock declined by 16.29% to $4.1. The market value of their outstanding shares is at $36.8 million. </li>
<li>Rapport Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) shares decreased by 7.65% to $8.7. The company's market cap stands at $317.5 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock decreased by 7.1% to $0.62. The market value of their outstanding shares is at $74.2 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) stock fell 7.03% to $4.1. The market value of their outstanding shares is at $151.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDMD

FGEN

OWLT

RAPP

TLPH

TOVX

UNCY

12 Health Care Stocks Moving In Monday's After-Market Session

MoonLake Immunotherapeutics shares are trading higher following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.

<a href="https://www.ft.com/content/5899ea69-e5fe-49f1-8ada-79f26c9254d8" title="https://www.ft.com/content/5899ea69-e5fe-49f1-8ada-79f26c9254d8">https://www.ft.com/content/5899ea69-e5fe-49f1-8ada-79f26c9254d8</a>

'Merck Held Talks To Buy Swiss Biotech MoonLake Immunotherapeutics For More Than $3B' - Financial Times

Wolfe Research analyst Andy Chen upgrades MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) from Peer Perform to Outperform and announces $61 price target.

Upgrades

Wolfe Research Upgrades MoonLake to Outperform, Announces $61 Price Target

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $66 price target.

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.74) by 14.86 percent. This is a 186.36 percent decrease over losses of $(0.22) per share from the same period last year.

Earnings

Earnings Beats

MoonLake Q1 EPS $(0.63) Beats $(0.74) Estimate

The additional capital strengthens MoonLake's balance sheet and provides financial support to rapidly advance sonelokimab and bring to market an investigational ~40 kDa humanized Nanobody designed to directly target sites of inflammation by inhibiting all relevant IL-17 dimers (namely the IL-17A/A, IL-17A/F, and IL-17F/F dimers) and penetrating difficult-to-reach inflamed tissues.

MoonLake Enters Agreement With Hercules Capital For Up To $500M In Non-Dilutive Capital

MoonLake Immunotherapeutics shares are trading higher after RBC Capital initiated coverage on the stock with an Outperform rating and announced a price target of $67.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Daniel Markowitz initiated coverage on West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with an Outperform rating and announced a price target of $275. West Pharmaceutical shares closed at $231.46 on Monday. <a href="https://www.benzinga.com/quote/WST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) with a Buy rating and announced a price target of $20. Alpha Cognition shares closed at $5.51 on Monday. <a href="https://www.benzinga.com/quote/ACOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Maheep Mandloi initiated coverage on Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Neutral rating and announced a price target of $28. Bloom Energy shares closed at $24.19 on Monday. <a href="https://www.benzinga.com/quote/BE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Joe Flynn initiated coverage on Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy rating and announced a price target of $2.5. Canaan shares closed at $1.07 on Monday. <a href="https://www.benzinga.com/quote/CAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Brian Abrahams initiated coverage on MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with an Outperform rating and announced a price target of $67. MoonLake shares closed at $38.67 on Monday. <a href="https://www.benzinga.com/quote/MLTX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-1024x601.png" alt="" class="wp-image-829880" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Initiation

ACOG

This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Press Releases

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Clear Street Launches Healthcare & Biotechnology Equity Research

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Financing

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

Comments

MoonLake

Noticias

Últimas noticias sobre MoonLake (NASDAQ:MLTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL